Summary
63 / 100 · Bulios Score
What speaks for it
- Out of every 100 CHF of revenue, 14 CHF is left as net profit.
- It earns 14 CHF a year on every 100 CHF of invested capital.
What to watch
- It cut its dividend by 16% last year.
- The share price is above the Bulios Fair Price.
- It missed profit estimates 6 times in the last 7 quarters.
- Earnings per share fell by 6.3% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 40.2 CHF for 1 CHF of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (CHF)
Diluted EPS (CHF)
- Analyst estimate
Revenue grew by 13% a year over 5 years. Over the last 3 years it grew by 3.9% a year. For the next fiscal year analysts expect revenue to grow by 3.7%.
Growth in detailDoes it make money?
Very wellWhere 100 CHF of revenue goes
- Cost of sales 32 CHF
- Sales and administration 47 CHF
- Taxes and other 7.3 CHF
- Net profit 14 CHF
Net profit, industry median (Medical - Instruments & Supplies) 8.1 CHF
Out of every 100 CHF of revenue, 14 CHF is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.0 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, stretched- Yield
- 1.47%
- Paid out of profit
- 59%
You receive $1.62 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 0
- Sell 0
No analyst has published a price target.
100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.